Navigation Links
Clinical trial identifies women most likely to benefit from vaginal mesh surgery
Date:3/10/2014

Certain women with vaginal prolapse are most likely to benefit from undergoing vaginal mesh surgery, a technique that has become controversial and is the focus of numerous lawsuits. The findings, which are published early online in Ultrasound in Obstetrics & Gynecology, provide valuable information regarding who should and should not be considered candidates for the surgery.

Vaginal prolapsewhen pelvic tissues weaken and the vaginal canal may protrude through the vaginal openingaffects roughly 10% to 20% of women. A significant number of patients require repeat surgeries to correct this recurring issue. They often undergo sacrospinous vaginal colpopexywhich involves attaching the vagina to surrounding tissue in the abdomen to hold it in placeor a surgical procedure that inserts a net-like implant called a vaginal mesh.

While studies suggest that vaginal mesh may reduce recurrence rates, it also has been linked with significant complications. (Indeed, vaginal mesh is the focus of a number of ongoing lawsuits.) To justify the potential complications associated with mesh use, it's important to identify women at high risk of prolapse recurrence.

Research suggests that a condition called levator avulsion is a major contributor to the development of pelvic floor prolapse and to its recurrence after surgery. This condition occurs when a woman suffers from an injury to the pelvic floor muscle during vaginal childbirth.

This information led Kamil Svabk, MD, PhD, of Charles University and General University Hospital in Prague, and his colleagues to compare sacrospinous vaginal colpopexy with vaginal mesh in patients with post-hysterectomy prolapse and levator avulsion, as diagnosed by ultrasound imaging.

The randomized clinical trial included 70 women: 36 underwent vaginal mesh surgery and 34 underwent sacrospinous vaginal colpopexy. At the one-year follow-up, ultrasound examinations revealed that there was one recurrence in the vaginal mesh group (2.8%), and 21 recurrences in the sacrospinous vaginal colpopexy group (61.8%). Dr. Svabk noted that despite the study's small size, the team was able to achieve significant results.

"By assessing patients prior to receiving treatment using pelvic floor ultrasound imaging, we are able to identify women who will benefit from vaginal mesh implantation over a conventional approach and dramatically reduce the risk of repeat surgery," said Dr. Svabk. "This is a win/win situation for our patients and for understanding the reasons behind varying success rates of conventional or less traditional treatments."


'/>"/>

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley
Source:Eurekalert

Related medicine news :

1. Myriad publishes clinical utility study for Prolaris
2. UNC receives more than $40 for global clinical trials unit to treat and prevent HIV
3. Clinical opinion published on use of maternal oxygen during labor
4. REACT clinical trial supports new approach of accelerated treatment for Crohns disease
5. Cell therapy shows remarkable ability to eradicate cancer in clinical study
6. Clinical trial success influenced by biomarker- and receptor-targeted therapies in NSCLC
7. Paper examines clinical and policy implications of intimate partner violence
8. $7 million multi-institutional contract creates New York City Clinical Data Research Network
9. Cedars-Sinai clinical trial studies vaccine targeting cancer stem cells in brain cancers
10. DynaMed™ and Nursing Reference Center™ Rated Higher Than Other Point-of-Care Reference Tools in New KLAS Report on Clinical Decision Support
11. Research for Her TM, an online clinical research registry, honored with distinguished national award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider of ... that Kyle Allain has joined the company as Vice President and General Manager ... provider, payor and managed care solutions. , A seasoned executive with more ...
(Date:4/24/2017)... ... April 24, 2017 , ... In ... be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into ... this type of healthcare model in the diagnosis and treatment of brain tumors. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant ... website. , Rod has been at the forefront of Gardant since it was founded ... Rod has overseen the opening of more than 40 new senior living communities. With ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for her ... good news for single women is that she put all the words in her ... 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her to ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... familiar. This makes it difficult for lab operators and management to assess these ... help them identify wasteful or unnecessary actions. , Created with the help ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... April 19, 2017  IRIDEX Corporation (Nasdaq: ... results for the first quarter 2017 after the close ... management team will host a corresponding conference call beginning ... Investors interested in listening to the conference call ... callers or (703) 326-3030 for international callers, using conference ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: